Maintenance of the postabsorptive plasma glucose concentration: insulin or insulin plus glucagon?
The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
The prevalent view is that the postabsorptive plasma glucose concentration is maintained within the physiological range by the interplay of the glucose-lowering action of insulin and the glucose-raising action of glucagon. It is supported by a body of evidence derived from studies of suppression of glucagon (and insulin, among other effects) with somatostatin in animals and humans, immunoneutralization of glucagon, defective glucagon synthesis, diverse mutations, and absent or reduced glucagon receptors in animals and glucagon antagonists in cells, animals, and humans. Many of these studies are open to alternative interpretations, and some lead to seemingly contradictory conclusions. For example, immunoneutralization of glucagon lowered plasma glucose concentrations in rabbits, but administration of a glucagon antagonist did not lower plasma glucose concentrations in healthy humans. Evidence that the glycemic threshold for glucagon secretion, unlike that for insulin secretion, lies below the physiological range, and the finding that selective suppression of insulin secretion without stimulation of glucagon secretion raises fasting plasma glucose concentrations in humans underscore the primacy of insulin in the regulation of the postabsorptive plasma glucose concentration and challenge the prevalent view. The alternative view is that the postabsorptive plasma glucose concentration is maintained within the physiological range by insulin alone, specifically regulated increments and decrements in insulin, and the resulting decrements and increments in endogenous glucose production, respectively, and glucagon becomes relevant only when glucose levels drift below the physiological range. Although the balance of evidence suggests that glucagon is involved in the maintenance of euglycemia, more definitive evidence is needed, particularly in humans.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Glucagon and regulation of glucose metabolism
Jiang, G., & Zhang, B. B. (2003) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00492.2002 · Cited by 905 · cited 4×
“Thus taken together, these data (2, 7, 10, 11, 16, 28, 43) are seemingly inconsistent with the putative role of glucagon in maintenance of the postabsorptive plasma glucose concentration (4, 18).”
BackgroundResultInfluentialAbnormal Alpha-Cell Function in Diabetes: Response to Carbohydrate and Protein Ingestion
Müller, W. A., Faloona, G. R., Aguilar-Parada, E., & Unger, R. H. (1970) · New England Journal of Medicine · doi:10.1056/nejm197007162830301 · Cited by 626 · cited 1×
“GIVEN EVIDENCE of absolute or relative hyperglucagonemia in patients with type 1 and type 2 diabetes (27, 29, 37, 38), Unger and Orci (48) first proposed that glucagon, in the setting of absolute or relative insulin deficiency, plays a role in the pathogenesis of diabetes.”
BackgroundThe essential role of glucagon in the pathogenesis of diabetes mellitus
Unger, R., & Orci, L. (1975) · The Lancet · doi:10.1016/s0140-6736(75)92375-2 · Cited by 599
Clutter, W. E., Bier, D. M., Shah, S. D., & Cryer, P. E. (1980) · Journal of Clinical Investigation · doi:10.1172/jci109840 · Cited by 576 · cited 1×
“Plasma epinephrine concentrations increased slightly, but not to biologically effective concentrations (6), after intravenous but not after oral diazoxide.”
BackgroundSelf-citationMitrakou, A., Ryan, C., Veneman, T., Mokan, M., Jenssen, T., Kiss, I., Durrant, J., Cryer, P., & Gerich, J. (1991) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1991.260.1.e67 · Cited by 558 · cited 4×
“Thus taken together, these data (2, 7, 10, 11, 16, 28, 43) are seemingly inconsistent with the putative role of glucagon in maintenance of the postabsorptive plasma glucose concentration (4, 18).”
BackgroundResultInfluentialSelf-citationContribution of Abnormal Muscle and Liver Glucose Metabolism to Postprandial Hyperglycemia in NIDDM
Mitrakou, A., Kelley, D., Veneman, T., Jenssen, T., Pangburn, T., Reilly, J., & Gerich, J. (1990) · Diabetes · doi:10.2337/diab.39.11.1381 · Cited by 317
Roden, M., Stingl, H., Chandramouli, V, Schumann, W. C., Hofer, A., Landau, B. R., Nowotny, P., Waldhäusl, W., & Shulman, G. I. (2000) · Diabetes · doi:10.2337/diabetes.49.5.701 · Cited by 288 · cited 1×
“Finally, nonesterified fatty acid elevations did not raise plasma glucose concentrations over the time frame studied (39, 47).”
BackgroundGlucose counterregulation: prevention and correction of hypoglycemia in humans
Cryer, P. E. (1993) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1993.264.2.e149 · Cited by 198 · cited 5×
“Given the primacy of regulated insulin secretion in the regulation of postabsorptive carbohydrate (and lipid) metabolism, what is the role of glucagon? Specifically, is maintenance of the postabsorptive plasma glucose concentration the result of the interplay of the glucose-lowering action of insulin (specifically, su…”
BackgroundResultSelf-citationFanelli, C., Pampanelli, S., Epifano, L., Rambotti, A. M., Ciofetta, M., Modarelli, F., Di Vincenzo, A., Annibale, B., Lepore, M., Lalli, C., et al. (1994) · Diabetologia · doi:10.1007/bf00404337 · Cited by 193
Acute noradrenergic activation induces insulin resistance in human skeletal muscle
Lembo, G., Capaldo, B., Rendina, V., Iaccarino, G., Napoli, R., Guida, R., Trimarco, B., & Sacca, L. (1994) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1994.266.2.e242 · Cited by 136 · cited 1×
“There were diazoxide dose-related increments in plasma norepinephrine concentrations, undoubtedly a reflection of a compensatory sympathetic neural response to the vasodilatory effect of the drug, but such hemodynamic sympathetic neural activation does not raise postabsorptive plasma glucose or nonesterified fatty aci…”
Background
Cited by
Chemerin Is a Novel Adipokine Associated with Obesity and Metabolic Syndrome
Bozaoglu, K., Bolton, K., McMillan, J., Zimmet, P., Jowett, J., Collier, G., Walder, K., & Segal, D. (2007) · Endocrinology · doi:10.1210/en.2007-0175 · Cited by 858
α-Cells of the Endocrine Pancreas: 35 Years of Research but the Enigma Remains
Gromada, J., Franklin, I., & Wollheim, C. B. (2007) · Endocrine Reviews · doi:10.1210/er.2006-0007 · Cited by 581
Impact of oral vancomycin on gut microbiota, bile acid metabolism, and insulin sensitivity
Vrieze, A., Out, C., Fuentes, S., Jonker, L., Reuling, I., Kootte, R. S., van Nood, E., Holleman, F., Knaapen, M., Romijn, J. A., et al. (2014) · Journal of Hepatology · doi:10.1016/j.jhep.2013.11.034 · Cited by 578
Physiology of Proglucagon Peptides: Role of Glucagon and GLP-1 in Health and Disease
Sandoval, D. A., & D'Alessio, D. A. (2015) · Physiological Reviews · doi:10.1152/physrev.00013.2014 · Cited by 498
Hormonal regulation of hepatic glucose production in health and disease
Lin, H. V., & Accili, D. (2011) · Cell Metabolism · doi:10.1016/j.cmet.2011.06.003 · Cited by 429
Metadata
- Authors
- Raju, B., & Cryer, P. E.
- Venue
- American Journal of Physiology-Endocrinology and Metabolism
- Publisher
- American Physiological Society
- Published
- 2005-08
- Volume
- 289
- Issue
- 2
- Pages
- E181-E186
- ISSN
- 0193-1849 (ISSN-L)
- 1522-1555
- OpenAlex
- W2161811597
- Cited by
- 42
- References
- 13
- FWCI
- 3.53
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Maintenance of the postabsorptive plasma glucose concentration: insulin or insulin plus glucagon? https://app.cochat.ai/papers/10.1152/ajpendo.00460.2004
- The paper
- Raju, B., & Cryer, P. E. (2005). Maintenance of the postabsorptive plasma glucose concentration: insulin or insulin plus glucagon? American Journal of Physiology-Endocrinology and Metabolism. https://doi.org/10.1152/ajpendo.00460.2004
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.